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Abstract
Introduction We have shown previously that overexpression of
constitutively active Akt or activation of Akt caused by
constitutively active Ras or human epidermal growth factor
receptor-2 (HER2) confers on breast cancer cells resistance to
chemotherapy or radiotherapy. As an expanded study we here
report differential responses in terms of phosphorylation and
activation of Akt as a result of treatment with doxorubicin in a
panel of breast cancer cell lines.
Methods The levels of Akt phosphorylation and activity were
measured by Western blot analysis with an anti-Ser473-
phosphorylated Akt antibody and by in vitro Akt kinase assay
using glycogen synthase kinase-3 as a substrate.
Results Within 24 hours after exposure to doxorubicin, MCF7,
MDA468 and T47D cells showed a drug-dose-dependent
increase in the levels of phosphorylated Akt; in contrast, SKBR3
and MDA231 cells showed a decrease in the levels of
phosphorylated Akt, and minimal or no changes were detected
in MDA361, MDA157 and BT474 cells. The doxorubicin-
induced Akt phosphorylation was correlated with increased
kinase activity and was dependent on phosphoinositide 3-
kinase (PI3-K). An increased baseline level of Akt was also found
in MCF7 cells treated with ionizing radiation. The cellular
responses to doxorubicin-induced Akt phosphorylation were
potentiated after the expression of Akt upstream activators
including HER2, HER3 and focal adhesion kinase.
Conclusion Taken together with our recent published results
showing that constitutive Akt mediates resistance to
chemotherapy or radiotherapy, our present data suggest that
the doxorubicin-induced phosphorylation and activation of Akt
might reflect a cellular defensive mechanism of cancer cells to
overcome doxorubicin-induced cytotoxic effects, which further
supports the current efforts of targeting PI3-K/Akt for enhancing
the therapeutic responses of breast cancer cells to
chemotherapy and radiotherapy.
Introduction
Cancer cells with an inherent or acquired capability to resist
induction of apoptosis at some point(s) in the signal cascade
pathway leading to cell death generally tend to be resistant to
chemotherapy or radiotherapy. The serine–threonine protein
kinase Akt has received much interest in recent years because
it suppresses apoptosis induced by chemotherapy or radio-
therapy through interaction with several critical molecules that
regulate or execute apoptosis. For instance, after activation,
Akt could do the following: it phosphorylates the proapoptotic
protein Bcl-2 partner, Bad, which binds to and blocks the
activity of Bcl-x, a factor in cell survival [1]; it inactivates cas-
pase-9, which initiates the caspase cascade leading to apop-
tosis [2]; it represses the forkhead transcription factor FKHRL-
1, which regulates the expression of the apoptosis-inducing
Fas ligand [3]; and it phosphorylates Iκ B, thereby promoting
the degradation of Iκ B and increasing the activity of the
nuclear factor κ B (NFκ B) [3,4].
The kinase activity of Akt is triggered after the interaction of its
pleckstrin homology domain with the lipid second messenger
phosphatidylinositol 3,4,5-trisphosphate, which is generated
by phosphoinositide 3-kinase (PI3-K). This interaction recruits
Akt from the cytoplasm to the inner cytoplasmic membrane,
ER = estrogen receptor; FBS = fetal bovine serum; FAK = focal adhesion kinase; FRNK = FAK-related non-kinase; GSK3 = glycogen synthase kinase-
3; HER2 = human epidermal growth factor receptor-2; IGF-I = type 1 insulin-like growth factor; p-Akt = Ser473-phosphorylated Akt; PI3-K = phos-
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where Akt undergoes conformational changes and is phos-
phorylated by the phosphatidylinositol-dependent kinases.
The activated Akt is then relocated to the cytoplasm and may
be transported further to the nucleus, phosphorylating a wide
spectrum of substrates including the molecules mentioned
above that are involved in the regulation of cell survival. PI3-K
itself is activated by multiple mechanisms, including the activa-
tion of growth factor receptor tyrosine kinases [5,6] and G pro-
tein-coupled receptors [7,8], integrin-mediated cell adhesion
[7,8], and the actions of oncogene products such as Ras
[9,10] and hormones such as estrogen [11-13]. By controlling
the levels of lipid second messengers, PI3-K regulates various
cellular processes, including growth, differentiation, survival,
migration and metabolism [14,15].
We have recently shown that expression of a constitutively
active Akt, or an increased activity of the human epidermal
growth factor receptor-2 (HER2)/PI3-K/Akt or Ras/PI3-K/Akt
pathway, leads to multidrug or radiation resistance in human
breast cancer cells [16-18]. In those studies we assessed the
sensitivity to chemotherapy (including doxorubicin) or radio-
therapy of breast cancer cells that contain a higher level of Akt
activity due to the overexpression of HER2, constitutively
active Ras or constitutively active Akt. To expand our previous
studies, we report here a differential pattern of responses of
breast cancer cell lines in terms of Akt phosphorylation and
activity as a result of treatment with doxorubicin. Depending on
the cell types, treatment of breast cancer cells with doxoru-
bicin may trigger a transient phosphorylation and activation of
Akt. This therapeutic intervention-triggered activation of Akt
depends on an inherent activity of PI3-K, and the capability of
the response is potentiated after the expression of Akt
upstream regulators including HER2, HER3 or the focal adhe-
sion kinase (FAK), but not by all the signals that are known to
affect Akt activity, an example of which is the estrogen-medi-
ated signal. Deprivation of the effect of estrogen did not alter
the responsiveness of MCF7 cells to doxorubicin-induced Akt
phosphorylation. Our data suggest that the therapeutic inter-
vention-triggered activation of Akt might contribute to the
resistance of breast cancer cells to doxorubicin. These results
provide further experimental evidence that justifies targeting
the PI3-K/Akt pathway to enhance the efficacy of breast can-
cer chemotherapy or radiotherapy.
Materials and methods
Cell lines and cell cultures
Eight breast cancer cell lines used in this study (MCF7,
MDA468, SKBR3, MDA157, MDA231, MDA361, BT474 and
T47D) were originally purchased from American Type Culture
Collection (Manassas, VA, USA). The cells were grown and
routinely maintained in Dulbecco's modified Eagle's medium/
F12 medium supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml
streptomycin. MCF7HER2 cells were described previously
[19]. All cells were grown in a 37°C incubator supplied with
5% CO2 and 95% air.
Western blot antibodies and other reagents
Antibodies directed against Akt, Ser473-phosphorylated Akt1
(p-Akt), Ser21/9-phosphorylated glycogen synthase kinase-3
(GSK3), Ser136-phosphorylated Bad and anti-HER2 mono-
clonal antibody were obtained from Cell Signaling Technology
(Beverly, MA, USA). Anti-HER3 antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-His
tag monoclonal antibody was ordered from Upstate Biotech-
nology (Charlottesville, VA, USA), as was the anti-FAK anti-
body that recognizes both FAK and FAK-related non-kinase
(FRNK), a dominant-negative mutant of FAK [20,21].
The humanized anti-HER2 monoclonal antibody trastuzumab
(Herceptin) was made by Genentech (San Francisco, CA,
USA). PI3-K-specific inhibitor LY294002 was obtained from
CalBiochem (San Diego, CA, USA), and the estrogen recep-
tor (ER) antagonist ICI 182,780 was purchased from Tocris
(Ballwin, MO, USA). Doxorubicin (Adriamycin) was ordered
from the pharmacy of MD Anderson Cancer Center. All other
reagents were purchased from Sigma-Aldrich (St Louis, MO,
USA).
cDNA and transient expression
The pcDNA3 expression construct containing HER3 was pro-
vided by Dr Xiaofeng Le (MD Anderson Cancer Center), and
the expression constructs of FAK and FRNK (pCMV-Myc)
were kindly provided by Dr Thomas Parsons (University of Vir-
ginia, Charlottesville, VA, USA). Transient transfection was
performed with the FuGENE 6 transfection kit, in accordance
with instructions provided by the manufacturer (Roche Diag-
nostic, Indianapolis, IN, USA).
Western blot analysis and Akt kinase assay
Western blot analysis and Akt kinase assay were performed as
described previously [16,19].
Cytoplasmic and nuclear fractionation
The method for cytoplasmic and nuclear fractionation was
adopted from the literature [22,23] with minor modifications. In
brief, pellets containing 2 × 107 cells were resuspended into
800 µl of buffer A (50 mM NaCl, 10 mM HEPES pH 8.0, 500
mM sucrose, 1 mM EDTA, 0.5 mM spermidine, 0.15 mM sper-
mine, 0.2% Triton X-100, 1 mM phenylmethylsulphonyl fluo-
ride, 2 mM Na3VO4, 25 µg/ml leupeptin, 25 µg/ml aprotinin).
After incubation on ice for 10 min, the cells were homogenized
with 10 strokes in a Dounce homogenizer. A small aliquot of
the cell homogenates was then examined under a microscope
to confirm that more than 98% of cells were lysed. After brief
centrifugation of the cell homogenates at 4°C, the supernatant
(cytoplasmic fraction) was collected and the pellet was
washed twice with 400 µl of buffer B (50 mM NaCl, 10 mM
HEPES pH 8, 25% glycerol, 0.1 mM EDTA, 0.5 mMAvailable online http://breast-cancer-research.com/content/7/5/R589
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spermidine, 0.15 mM spermine) and then resuspended in 150
µl of buffer C (350 mM NaCl, 10 mM HEPES pH 8.0, 25%
glycerol, 0.1 mM EDTA, 0.5 mM spermidine, 0.15 mM sper-
mine) with gentle rocking for 30 min at 4°C [22]. After centrif-
ugation, the supernatant (nuclear fraction) was collected. The
amounts of protein in the cytoplasmic and nuclear fractions
were determined with the Bradford method (Bio-Rad, Her-
cules, CA, USA).
Ionizing radiation
Cells grown on Petri dishes were irradiated with γ -rays from a
high-dose-rate 137Cs unit (4.5 Gy/min) at room temperature
(25 – 27°C), as described previously [17,19]. After irradiation,
the cells were harvested by trypsinization.
Results
Differential responses in the baseline levels of Akt 
phosphorylation and kinase activity in a panel of breast 
cancer cell lines after treatment with doxorubicin
To assess the cellular responses in breast cancer cells in the
baseline levels of Akt phosphorylation and activity as a result
of doxorubicin treatment, we first examined the level of Akt
phosphorylation and activation in MCF7 breast cancer cells
after treatment with doxorubicin. Figure 1a shows a time-
dependent induction in the levels of p-Akt with reference to the
total levels of Akt in MCF7 cells treated with 1 µM doxorubicin,
a dose that we have shown previously to induce apoptosis in
the cells [16,18]. An increase in p-Akt level was detected as
early as after 1 hour of exposure of the cells to doxorubicin,
and a robust increase in the level of p-Akt was observed 24
hours after treatment.
We next expanded the experiment in a panel of eight breast
cancer cell lines treated with increasing concentrations (0.125
to 1 µM) of doxorubicin for 24 hours in culture medium supple-
mented with 10% FBS. Interestingly, it was found that the
changes in the levels of p-Akt varied between the cell lines
after the treatment. In comparison with control cells, which
were kept untreated for 24 hours in the same type of culture
medium, MCF7, MDA468 and T47D cells showed a dose-
dependent increase in p-Akt levels; in contrast, SKBR3 and
MDA231 cells showed a dose-dependent decrease, and no or
minimal change was detected in MDA361, MDA157 and
BT474 cells (Fig. 1b). As expected, no changes in total Akt
expression were found in the cell lines after the treatment.
These results suggest that genetic context among individual
Figure 1
Differential responses to doxorubicin-induced phosphorylation of Akt in a panel of human breast cancer cells Differential responses to doxorubicin-induced phosphorylation of Akt in a panel of human breast cancer cells. (a) MCF7 cells were exposed to 1 µM 
doxorubicin (Doxo) for the indicated periods in culture medium supplemented with 10% fetal bovine serum (FBS). The cells were then harvested and 
prepared for Western blot analyses with antibodies directed against Ser473-phosphorylated Akt (p-Akt) and total Akt. The densitometric levels of p-
Akt at each time point were normalized to the corresponding levels of total Akt and are shown in the bar graph. (b) A panel of eight indicated breast 
cancer cell lines were treated with 0.125 to 1 µM doxorubicin for 24 hours in culture medium supplemented with 10% FBS. After treatment the indi-
vidual cell lines were harvested, lysed and subjected to Western blot analyses with antibodies against p-Akt and total Akt.Breast Cancer Research    Vol 7 No 5    Li et al.
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cell lines might have a role in determining the cellular
responses to the treatment.
To confirm that the phosphorylation of Akt induced by doxoru-
bicin was associated with an increased Akt kinase activity, we
assessed Akt activity by in vitro Akt kinase assay on two
known Akt substrates, Bad and GSK3, in MCF7 cells. Figure
2a shows that, in comparison with untreated MCF7 cells and
with the cells treated with type 1 insulin-like growth factor
(IGF-1), the cells treated with doxorubicin contained an
increased level of p-Akt, which was comparable to the
increase of p-Akt level stimulated by IGF-1. Treatment of the
cells with ionizing radiation induced a similar increase in the
level of p-Akt. The increases in p-Akt level induced by doxoru-
bicin or radiation were associated with increased Akt kinase
activities measured by the Akt in vitro kinase assay (Fig. 2b).
We found that the Akt protein immunoprecipitated from doxo-
rubicin-treated or γ -ray-irradiated cells phosphorylated both
Bad and GSK3 as strongly as the Akt protein from the IGF-1-
treated cells.
As another measure of the functional status of Akt after treat-
ment with doxorubicin or ionizing radiation, we also examined
the translocation of Akt from the cytoplasm to the nucleus. To
allow the detection of the signals of Akt from cytoplasmic to
nuclear translocation, we raised the level of Akt expression in
MCF7 cells by transient transfection of the cells with a His-
tagged Akt1 expression construct 48 hours before harvest.
Both the doxorubicin-induced and radiation-induced increases
in Akt phosphorylation were associated with increased trans-
location of Akt from the cytoplasm to the nucleus (Fig. 2c).
To determine the extent to which the doxorubicin-induced acti-
vation of Akt is regulated by the PI3-K pathway, we explored
this question with MCF7 cells, which express a relatively low
baseline level of p-Akt, and MDA468 cells, which express a
relatively high baseline level of p-Akt because of the mutation
status of PTEN (phosphatase and tensin homolog deleted on
chromosome ten) in the cells [24]. We found that an overnight
(16 hours) exposure of the cells to LY294002, a PI3-K-spe-
cific inhibitor, remarkably abolished the increase in Akt phos-
phorylation after treatment with doxorubicin in both MCF7 and
MDA468 cells (Fig. 2d). The results indicate that the doxoru-
bicin-induced phosphorylation and activation of Akt were
mediated through a PI3-K dependent pathway.
Roles of HER family members in doxorubicin-induced 
activation of Akt
Because the doxorubicin-induced activation of Akt is depend-
ent on PI3-K activity, we proposed that the breast cancer cells
with compelling molecular components of the PI3-K pathway
might show an enhanced cellular response to doxorubicin-
induced activation of Akt. The HER family members are impor-
tant upstream regulators of the PI3-K/Akt pathway and are
known to be important in the progression of breast cancer and
its resistance to chemotherapy or radiotherapy [25,26]. To
determine the extent to which HER family members might
potentiate the cellular response to doxorubicin-induced activa-
Figure 2
Functional analysis of Akt phosphorylation in human breast cancer cells after treatment with doxorubicin Functional analysis of Akt phosphorylation in human breast cancer cells after treatment with doxorubicin. (a) MCF7 cells were exposed to 1 µM dox-
orubicin (Doxo) for 24 hours, or irradiated (XRT) with X-rays (5 Gy) and then cultured for a further 24 hours in culture medium supplemented with 
10% fetal bovine serum (FBS). MCF7 cells stimulated for 15 min with 10 nM type 1 insulin-like growth factor (IGF-1) were used as a positive con-
trol. Untreated (Untx) and the treated MCF7 cells were harvested, lysed and subjected to Western blot analyses with antibodies against Ser473-
phosphorylated Akt (p-Akt) and total Akt. (b) MCF7 cells transiently transfected with a His-tagged Akt1 expression construct were left untreated or 
treated as in (a). Akt1 was immunoprecipitated by using an anti-His tag monoclonal antibody and then assayed for in vitro kinase activities for phos-
phorylation on Bad and glycogen synthase kinase-3 (GSK3). (c) Cytoplasmic and nuclear fractionations from untreated, doxorubicin-treated and γ -
ray-irradiated MCF7 cells were separated as described in Materials and Methods. Equal amounts (40 µg) of cytoplasmic fraction (Cy) and nuclear 
fraction (Nu) from each sample were subjected to Western blot analysis to determine the distribution of Akt after treatment with doxorubicin or ioniz-
ing radiation. β -Actin and poly(ADP-ribose) polymerase (PARP) were used as markers of the cytoplasmic and nuclear fractions, respectively. (d) 
MCF7 or MDA468 cells were pre-exposed to 10 µM LY294002 for 2 hours before treatment with 1 µM doxorubicin for 24 hours. After treatment the 
cells were harvested, lysed and subjected to Western blot analyses with antibodies against p-Akt and total Akt.Available online http://breast-cancer-research.com/content/7/5/R589
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tion of Akt in breast cancer cells, we assessed the effect of
treatment with doxorubicin (0.5 to 1 µM) on p-Akt levels in
MCF7 cells transfected with a HER2 expression construct
(MCF7HER2 cells). In comparison with control vector-trans-
fected MCF7 cells (MCF7neo), MCF7HER2 cells showed not
only a higher baseline level of p-Akt (Fig. 3, compare lanes 1
and 7) but also an enhanced response to the doxorubicin-
induced increase in Akt phosphorylation (Fig. 3, compare
lanes 1 to 3 with lanes 7 to 9). A caveat is that it is unlikely that
the enhancement was caused by an additive effect of Akt
phosphorylation by doxorubicin treatment and HER2 overex-
pression in the cells, because treatment of MCF7neo cells
with trastuzumab also decreased the level of doxorubicin-
induced phosphorylation of Akt. As expected, we detected no
changes in the level of total Akt. The increase in the levels of
p-Akt in MCF7neo and MCF7HER2 cells by doxorubicin was
markedly diminished by pretreatment with trastuzumab, which
downregulates HER2 in these cells (Fig. 3, compare lanes 1
to 3 with lanes 4 to 6, and lanes 7 to 9 with lanes 10 to 12).
Taken together, these results indicate that the higher level of
HER2 in MCF7HER2 cells potentiates the response of the
cells to doxorubicin-induced activation of Akt.
Interestingly, some cell lines including SKBR3 cells showed a
decline in the level of p-Akt after treatment with doxorubicin
(Fig. 1), despite the fact that SKBR3 cells express an appreci-
able level of HER2 [27,28]. A notable difference between
MCF7 and SKBR3 cells is that the former expresses HER3
whereas the latter has no detectable level of HER3 expression
[16]. Of the HER family members, HER3 contains the most
PI3-K-binding sites, but it is kinase-deficient and is mainly acti-
vated though heterodimerization with other HER members
[29]. We proposed that an insufficient level of HER3 expres-
sion might affect the response of SKBR3 cells to treatment
with doxorubicin. To test this hypothesis we transiently trans-
fected SKBR3 cells with a HER3 expression construct. Figure
4 shows that, in comparison with control vector-transfected
SKBR3 cells, transient expression of HER3 prevented the
decline in the level of p-Akt after doxorubicin treatment in
SKBR3 cells. It is noteworthy that, in this particular experiment,
HER3 was only transiently transfected into the SKBR3 cells,
with an estimated 10 to 15% transfection efficiency. Given the
result from the mixed (transfected and untransfected) cells, it
is reasonable to speculate that selected clonal or pooled
HER3-expressing SKBR3 cells would exhibit a pattern of
response similar to that observed in MCF7 cells.
Exposure of the transiently transfected cells to doxorubicin
also led to a decrease in the level of HER3, the mechanism of
which is unknown. We speculate that it might be related to a
degradation of the protein after heterodimerization with HER2.
Figure 3
Potentiation to doxorubicin-induced Akt phosphorylation in MCF7 cells  after expressing high levels of HER2 Potentiation to doxorubicin-induced Akt phosphorylation in MCF7 cells 
after expressing high levels of HER2. Control vector-transfected MCF7 
cells (MCF7neo) and MCF7 transfectants expressing high levels of 
human epidermal growth factor receptor-2 (MCF7HER2) were left 
untreated or were treated with 0.5 or 1 µM doxorubicin (Doxo) for 24 
hours. Separate dishes of MCF7neo and MCF7HER2 cells were pre-
treated with 20 nM trastuzumab (Herceptin) 24 hours before treatment 
with doxorubicin. After treatment the cells were harvested, lysed and 
subjected to Western blot analyses with antibodies against HER2, 
Ser473-phosphorylated Akt (p-Akt) and total Akt. The densitometric 
levels of p-Akt were normalized to the respective levels of total Akt in 
each lane and are shown in the bar graph.
Figure 4
Effect of HER3 expression on decrease in Akt phosphorylation in  SKBR3 cells after doxorubicin treatment Effect of HER3 expression on decrease in Akt phosphorylation in 
SKBR3 cells after doxorubicin treatment. SKBR3 cells were transiently 
transfected with a control vector (pcDNA3) or a HER3 expression con-
struct for 24 hours, and then exposed to 0.125 to 1 µM doxorubicin for 
a further 24 hours. After treatment the cells were harvested, lysed and 
subjected to Western blot analyses with antibodies against HER3, 
Ser473-phosphorylated Akt (p-Akt) and total Akt. The densitometric 
levels of p-Akt were normalized to the respective levels of total Akt in 
each lane and are shown in the bar graph.Breast Cancer Research    Vol 7 No 5    Li et al.
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Nevertheless, the transient expression of HER3 in only a small
fraction of the cell population (10 to 15%; data not shown)
prevented the decline in p-Akt after treatment with doxorubicin
in a HER2-overexpressing cell line (SKBR3) suggests a poten-
tial cooperative role of HER2 and HER3 in the increase in Akt
activity after treatment with doxorubicin. Thus, the ability of
HER2 to potentiate the cellular response of Akt phosphoryla-
tion or activation after treatment with doxorubicin depends on
the cell types.
Involvement of FAK in doxorubicin-triggered 
phosphorylation and activation of Akt
To broaden the implication of our findings, we sought to
assess possible roles of other signal pathways that might also
potentiate the cellular response of Akt phosphorylation of
MCF7 cells after treatment with doxorubicin. In addition to the
HER family members, the FAK pathway is also known to mod-
ulate the PI3-K pathway. The FAK pathway is regulated by the
interaction between extracellular matrix receptors and
integrins, and is often augmented in human breast cancer cells
[30,31]. We therefore transiently transfected MCF7 cells with
an expression construct of FAK or its dominant-negative coun-
terpart, FRNK. In comparison with control vector-transfected
cells, which exhibited a LY294002-sensitive increase in the
level of p-Akt over baseline, FAK-transfected cells had a higher
p-Akt level both at baseline and after treatment with doxoru-
bicin and were sensitive to LY294002 (Fig. 5). In contrast,
transfection of MCF7 cells with FRNK led to a lower phospho-
rylation level of Akt after treatment with doxorubicin. Irrespec-
tive of the expression of FAK or FRNK, the level of total Akt
remained unchanged. Taken together, these results suggest
that molecular components, such as FAK and HER3, that
enhance the cellular sensitivity and responsiveness for PI3-K
activation might potentiate the cellular responses of Akt phos-
phorylation to treatment with doxorubicin.
Effects of estrogen on doxorubicin-induced 
phosphorylation and activation of Akt
To determine whether the signaling pathways known to mod-
ulate the activity of PI3-K/Akt might unanimously potentiate the
cellular response of Akt phosphorylation to treatment with dox-
orubicin, we examined the effect of doxorubicin on the level of
p-Akt in MCF7 cells cultured in medium supplemented with an
ER antagonist or in estrogen-depleted medium. Estrogen is
known to be involved in the regulation of Akt phosphorylation
in both ER-positive and ER-negative breast cancer cells
[12,32,33]. In comparison with vehicle-treated cells, MCF7
cells stimulated with estrogen (estradiol) showed a higher
level of p-Akt, which was decreased when an ER antagonist
(ICI 182,780) was present in the culture medium (Fig. 6a). In
contrast with the results shown in Figs 4 and 5, we observed
no difference in the levels of p-Akt after doxorubicin treatment
in MCF7 cells cultured in regular 0.5% FBS medium, charcoal-
stripped FBS (that is, estrogen-depleted) medium, or regular
0.5% FBS medium plus ICI 182,780 (Fig. 6b). These results
suggested that at least the PI3-K signaling regulated by
estrogen does not potentiate the cellular responsiveness to
doxorubicin-induced phosphorylation of Akt.
Discussion
In our present study we found that the activity of Akt, an impor-
tant signal molecule that promotes cell survival and confers
cellular resistance to chemotherapy and radiotherapy as
shown by us [16,18,19] and others [34,35], was transiently
elevated in a subset of breast cancer cell lines as a result of
exposure to doxorubicin, a chemotherapeutic agent commonly
used to treat patients with breast cancers. Activation of Akt in
MCF7 cells after exposure to doxorubicin was reported earlier,
but the mechanism was not explored in detail [34,35]. We
noted here that, in comparison with resting (non-stimulated)
cells, in which most Akt was found in the cytoplasm, exposure
of the cells to doxorubicin or ionizing radiation led to a
relocation of Akt to the nucleus. It is noteworthy that several
antiapoptotic substrates of Akt are nuclear proteins. This sub-
Figure 5
Potentiation of cellular response to doxorubicin-induced Akt phosphor- ylation in MCF7 cells by FAK Potentiation of cellular response to doxorubicin-induced Akt phosphor-
ylation in MCF7 cells by FAK. MCF7 cells were transiently transfected 
for 24 hours with a control vector (pcDNA3.1), a focal adhesion kinase 
(FAK) expression construct or a FAK-related non-kinase (FRNK) expres-
sion construct, followed by exposure to 1 µM doxorubicin (Doxo) for a 
further 24-hour of culture, with or without the addition of the phosphoi-
nositide 3-kinase-specific inhibitor LY294002 (20 µM) 16 hours before 
the end of exposure to doxorubicin. After treatment the cells were har-
vested, lysed and subjected to Western blot analyses with antibodies 
against FAK, FRNK, Ser473-phosphorylated Akt (p-Akt) and total Akt. 
The densitometric levels of p-Akt were normalized to the respective lev-
els of total Akt in each lane and are shown in the bar graph.Available online http://breast-cancer-research.com/content/7/5/R589
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cellular translocation of Akt is important for cells to overcome
the death signals initiated by treatment with doxorubicin or ion-
izing radiation. Taken together with our previous results [16-
18], the present results suggest that doxorubicin-triggered
activation of Akt has a role in the resistance of breast cancer
cells to this drug and that the same might apply to
radiotherapy.
Because the overall cellular sensitivity of breast cancer cells to
chemotherapy or radiotherapy is attributed to multiple intrinsic
and extrinsic factors, such as p53 status, Bcl-2/Bax levels,
expression of multiple drug resistance proteins, and hypoxic
status, a caveat is that our data do not necessarily imply that
one group of breast cancer cells showing increases in the
level of p-Akt after chemotherapy or radiotherapy would abso-
lutely be more chemoresistant or radioresistant than the
another group of breast cancer cells without showing such a
response. Rather, the data indicate that the activation and
phosphorylation of Akt triggered by chemotherapy or radio-
therapy contribute to the overall cellular sensitivity to these
conventional therapies.
Several questions remain to be fully answered. First, why was
Akt activation after treatment with doxorubicin found in only
some of the breast cancer cell lines we tested? Apparently,
cells must be equipped with certain molecular components
that enable them to react to signals induced by chemotherapy
or radiotherapy. We found that the drug-triggered activation of
Akt depends on the activity of PI3-K, which can be activated
by several known pathways, some of which we have explored
in the present study. Which pathway is activated depends on
the genetic context and functional status of the signal
transduction network in individual cell types. In our study,
MCF7 cells transiently expressing a high level of HER2 poten-
tiated the response of the cells to the doxorubicin-induced
activation of Akt. This result is consistent with those shown
recently by us [16,19] and others [36-38] indicating that
HER2 expression in breast cancer cells might render them
more resistant to chemotherapy or radiotherapy.
However, a high level of HER2 expression alone might not be
sufficient to mediate this response. For example, we detected
no change in the level of p-Akt in BT474 breast cancer cells
after treatment with doxorubicin, even though they expressed
a high level of HER2. SKBR3, another breast cancer cell line
that expresses high levels of HER2, even showed a reduced
level of p-Akt after treatment with doxorubicin. Expression of a
transient transfected HER3 in the SKBR3 cells prevented this
decline, indicating that heterodimerization and crosstalk
between HER2 and HER3 might be important in mediating the
downstream pathway that leads to Akt activation in breast can-
cer cells after treatment with doxorubicin. This might explain
the negative findings from a recent clinical study reporting that
HER2 overexpression does not seem to predispose to locore-
gional recurrence for breast cancer patients treated with neo-
adjuvant doxorubicin-based chemotherapy, mastectomy and
radiotherapy [39].
A second question is what molecular executioner leads to the
activation of Akt after chemotherapy or radiotherapy. Are any
soluble factors or non-secreted membrane-bound ligands
involved, or is the PI3-K/Akt pathway activated directly and
Figure 6
Potential involvement of estrogen-mediated signaling on doxorubicin-induced Akt phosphorylation Potential involvement of estrogen-mediated signaling on doxorubicin-induced Akt phosphorylation. (a) MCF7 cells grown to subconfluence were 
exposed to 1 µM ICI 182,780 (an estrogen receptor antagonist) or the vehicles (dimethyl sulfoxide [DMSO] and ethanol [EtOH]) for 30 min, and 
then treated with or without 10 nM estradiol (E2) for a further 30 min. Cell lysates were prepared for Western blot analysis with antibodies against 
Ser473-phosphorylated Akt (p-Akt) and total Akt. (b) MCF7 cells were cultured in regular 0.5% fetal bovine serum (FBS) medium, charcoal-stripped 
(CS) FBS medium, or regular 0.5% FBS plus 1 µM ICI 182,780. The cells were then treated with 0.25 to 1 µM doxorubicin (Doxo) for 24 hours. 
After treatment the cells were harvested, lysed and subjected to Western blot analyses with antibodies against p-Akt and total Akt.Breast Cancer Research    Vol 7 No 5    Li et al.
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autonomously? In our study, we demonstrated that several
different mechanisms, two of which are the expression of
HER2 and of FAK, might enhance the doxorubicin-induced
activation of Akt. Each mechanism activates PI3-K but does so
through different ligands. Interference with these pathways by
the anti-HER2 monoclonal antibody trastuzumab or by a dom-
inant-negative mutant FAK (FRNK) abolished the drug-trig-
gered activation of Akt mediated by HER2 and FAK,
respectively. An interesting finding from our studies is that not
all stimuli that lead to PI3-K activation enhance the drug-trig-
gered activation of Akt. For example, abnormal estrogen expo-
sure is associated with an increased risk of breast cancer, and
estrogen is known to activate Akt via a non-nuclear estrogen-
signaling pathway involving the direct interaction of ER with
PI3-K [40].
The ER isoform ERα  binds to the p85α  regulatory subunit of
PI3-K in a ligand-dependent manner. Stimulation with estro-
gen increases ERα -associated PI3-K activity, leading to the
activation of Akt. This interaction between ER and p85α  is
independent of gene transcription and does not involve phos-
photyrosine adapter molecules or Src-homology domains of
p85α  [40]. We found that the ER antagonist ICI 182,780
blocked estrogen-induced Akt activation in the ER-positive
MCF7 cells but did not affect doxorubicin-induced Akt activa-
tion. Depletion of estrogen from the culture medium did not
affect the doxorubicin-induced activation of Akt either. These
data suggest that estrogen-induced signals, whether depend-
ent on ER or not, are not involved in the pathway that enhances
the doxorubicin-induced activation of Akt.
In fact, this atypical activation of Akt seems not to be limited to
doxorubicin or ionizing radiation. We have observed that treat-
ment of MCF7 cells with several different drugs (paclitaxel, 5-
flurouracil and gemcitabine) that act through different mecha-
nisms can also induce Akt phosphorylation, although the
response and the timing and dose required for this effect var-
ied between the drugs tested (data not shown). Cellular stress
such as hypoxia and ultraviolet radiation has been reported by
others to induce PI3-K-dependent Akt activation [41-43].
Thus, inherent properties of individual cell types, rather than
specific cell death signals, might determine whether Akt is
activated after cells are exposed to stresses. Cancer cells with
functional aberrations, such as overexpression of HER family
members or increased cell adhesion potential, are probably
more capable than noncancerous cells of activating Akt as a
defensive mechanism against external detrimental stimuli,
which justifies a novel approach of targeting the PI3-K/Akt for
chemosensitization or radiosensitization.
In summary, doxorubicin might cause a PI3-K-dependent
increase of Akt activity in breast cancer cells. Together with
other recent results of ours [16-18], the present observations
suggest that clinical benefits in treating patients with breast
cancer could be obtained with appropriate combinations of
novel Akt inhibitors and conventional chemotherapeutic drugs
or ionizing radiation.
Conclusion
We found that the activities of Akt are increased in selected
cell lines treated with doxorubicin, which is a PI3-K-dependent
process and is potentiated after overexpression of HER2/
HER3 receptor tyrosine kinases or FAK nonreceptor tyrosine
kinase. This therapeutic intervention (doxorubicin)-triggered
activation of Akt might have a role in affecting the overall ther-
apeutic responses of cancer cells to the treatment. Clinical
benefits in the treatment of breast cancer patients could be
obtained with appropriate combinations of novel Akt inhibitors
and conventional chemotherapeutic drugs or ionizing radia-
tion. Our observations further justify the efforts of targeting
PI3-K/Akt for enhancing the therapeutic responses of breast
cancer cells to the conventional therapies.
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